Exenatide vs Decapeptide-12
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss AgonistsCognitive Enhancement
ExenatideSkin & Cosmetic
Decapeptide-12- Summary
- Exenatide is a GLP-1 receptor agonist derived from the Gila monster lizard peptide exendin-4, with 53% homology to human GLP-1 and natural resistance to DPP-4 degradation. Available as twice-daily (Byetta) or once-weekly (Bydureon) formulation, it is also being studied for Parkinson's disease neuroprotection.
- Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
- Half-Life
- ~2.4 hours (Byetta/twice-daily); Bydureon BCISE: weekly via microsphere release
- Not applicable (topical)
- Admin Route
- SubQ
- Topical
- Research
- —
- —
- Typical Dose
- 5 mcg, titrate to 10 mcg
- 5 ppm (0.0005%) concentration
- Frequency
- Twice daily
- Twice daily (AM and PM)
- Key Benefits
- Blood glucose control in type 2 diabetes
- Weight loss (average 2–3 kg in clinical trials)
- Once-weekly extended-release formulation available
- Reduces appetite and food intake
- Possible neuroprotective in Parkinson's disease (Phase II trials)
- Reduces systemic inflammation
- May protect pancreatic beta cells
- Cardiovascular neutral or potentially protective
- Reduces hyperpigmentation and dark spots
- Evens skin tone and improves radiance
- Inhibits post-inflammatory hyperpigmentation
- Well-tolerated alternative to hydroquinone
- Effective for melasma and age spots
- Non-cytotoxic to melanocytes
- Side Effects
- Nausea (most common, especially initially)
- Vomiting
- Diarrhea
- Headache
- +4 more
- Generally very well-tolerated
- Rare mild irritation or sensitivity in some skin types
- Results may take several weeks to become visible
- Stacks With
- —
- —